



1,500 radiation therapy centers choose myQA®

myQA® has been selected by over 1,500 customers around the world as their trusted global Quality Assurance platform to integrate QA applications, people, and know-how.

Milan, Italy, April 25, 2019 – IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announced at the ESTRO 38 congress, that it has reached the milestone of 1,500 myQA® customers worldwide. Since the first release of myQA in 2015, IBA has rapidly expanded its customer base across the global radiation therapy community and today serves the largest QA platform customer base by far. This growth has been driven by the need to improve the integration of quality assurance across all QA applications, departments, and professionals in radiation therapy and beyond.

With myQA, IBA Dosimetry has been the innovation leader for quality assurance platform solutions and has set a new standard in making quality checks for cancer treatments safer and more efficient. Compared to other solutions, myQA integrates all modern radiation therapy QA needs, from Beam Scanning and Machine QA, to Imaging QA and Patient QA. The generic test functionality enables users to integrate their individual site-specific tests into the global QA platform

*"In 2015, IBA Dosimetry has introduced the world's first quality assurance platform solution to the radiation therapy market. With a very fast market adoption, over 1,500 healthcare centers worldwide trust myQA today," said **Jean-Marc Bothy, President of IBA Dosimetry**. "This success is also an incentive for us and our collaboration partners to continue lead QA innovations into the future. With continued enhancements and additional functionality we are enabling medical physicists and radiation therapy experts around the world to provide more efficient QA and safer patient treatments."*

About myQA® Global QA Platform

The myQA software platform connects QA applications, people, and know-how through a Central Database, as well as dedicated site-to-site QA benchmarking options. It offers full support to its users by integrating the entire QA workflow, and provides access to all software application modules and data from one intuitive interface. Users also have a complete, instant overview of their results with the myQA Cockpit. myQA integrates all major tasks of the QA workflow, from Beam Scanning and Machine QA, to Imaging QA and Patient QA. Furthermore, users can also integrate their individual hospital tests into myQA.

myQA integrates colleagues and sites by providing access to QA data and applications from one central software platform and one central database.

For more information visit <https://www.iba-dosimetry.com/solutions/myqa/>

Press release | 25/04/2019

IBA | Dosimetry GmbH

Bahnhofstr. 5 | 90592 Schwarzenbruck | Germany | T +49 9128 607 0 | F +49 9128 607-10

Registration Court: Local Court (Amtsgericht) Nürnberg, HRB 4262

Managing Directors (Geschäftsführer): Olivier Legrain, Jean-Marc Bothy, Soumya Chandramouli

Dosimetry-info@iba-group.com | www.iba-dosimetry.com

**PROTECT +
ENHANCE +
SAVE LIVES**



*** ends ***

About IBA Dosimetry

IBA Dosimetry GmbH innovates radiation therapy, proton therapy and diagnostic imaging through integrated Quality Assurance solutions that are efficient, intuitive and that provide peace of mind for healthcare professionals and patients around the world. The myQA® Global QA Platform is the backbone for Integrated Quality Assurance solutions. IBA Dosimetry has more than 220 international employees in four offices in Germany, France, China and USA.

Find more information at: www.iba-dosimetry.com

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

Media Contact:

Ralf Schira, Director Global Marketing, IBA Dosimetry, ralf.schira@iba-group.com